Note from BriaCell Management – October is Breast Cancer Awareness Month
October 01 2020 - 5:30AM
BriaCell Therapeutics Corp.
("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXF) is a clinical-stage
biotechnology company specializing in targeted immunotherapy for
advanced breast cancer. October is Breast Cancer Awareness Month,
an annual campaign to increase awareness of the disease.
Significant progress has been made in breast cancer support,
prevention, detection, diagnosis, treatment and care – yet the
estimated 43,000 deaths per year in the U.S. still indicates a
grave need for more effective breast cancer treatments.
Breast Cancer: Facts
& Statistics (U.S.)
Per the American Cancer Society 2020 report:
- Breast cancer is the most
frequently diagnosed cancer in women, with 276,480 women and 2,620
men expected to be diagnosed with invasive breast cancer in
2020;
- The average risk of a woman
developing breast cancer sometime in her life is about 13%. This
means there is a 1 in 8 chance she will develop breast cancer;
- Approximately 30% of breast cancers
occur in women younger than 55 and 44% occur in women older than
65;
- Breast cancer deaths in 2020 are
estimated at 42,690 (42,170 women, 520 men), making breast cancer
the 2nd leading cause of cancer death in women (after lung
cancer).
Note from
BriaCell Management
October 1st kicks off Breast Cancer Awareness
Month; yet sadly, for millions of Americans touched by the pain and
death of breast cancer, their Awareness is eternal. BriaCell’s
clinical aim to attack and destroy breast cancer tumors is also
eternal, as we tirelessly advance our targeted immunotherapy
clinical program.
Breast Cancer Awareness Month brings the
awareness that BriaCell is not treating ‘subjects’ or ‘n=’. We are
treating women – mothers, daughters, sisters, wives,
friends. Breast cancer kills 117 women in
the U.S. each day. BriaCell’s work has already demonstrated
clinical benefit to some women (i.e. tumor shrinkage without
serious side effects) who had failed multiple prior treatments.
BriaCell has truly emerged in 2020, with a
flurry of major corporate and clinical developments, each one
transformational on its own, including the identification of
additional 'biomarkers’ – a possible predictor
of high-responding patients and a relationship with Mount
Sinai to investigate molecular and pathologic biomarkers in early
2020. In early 2020, also, BriaCell announced a remarkable
responder who had failed 13 prior chemotherapy regimens prior to
BriaCell’s treatment. She had experienced a highly remarkable
reduction in tumors that had metastasized to areas outside of the
breasts. Impressively, a metastasized tumor behind her left eye
orbital region, which had pushed the eye forward from the skull,
had completely disappeared. Additionally, an investigator grant was
awarded by Merck & Co., Inc. to provide pembrolizumab
[KEYTRUDA®] for the Combination Study of Bria-IMT™ with
KEYTRUDA® in advanced breast cancer patients.
William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
About
BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding
Forward-Looking Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024